{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:56:49Z","timestamp":1781704609639,"version":"3.54.5"},"reference-count":23,"publisher":"Norwegian Medical Association","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.17.1110","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T08:23:28Z","timestamp":1542097408000},"source":"Crossref","is-referenced-by-count":8,"title":["Psychedelic drugs in the treatment of anxiety, depression and addiction"],"prefix":"10.4045","volume":"138","author":[{"given":"Tor-Morten","family":"Kvam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lowan H.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole A.","family":"Andreassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"ref=1","unstructured":"Grof\u00a0S, Goodman\u00a0LE, Richards\u00a0WA et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry 1973; 8: 129\u201344. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4140164&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1159%2F000467984"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Rucker\u00a0JJ, Jelen\u00a0LA, Flynn\u00a0S et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol 2016; 30: 1220\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27856684&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881116679368","DOI":"10.1177\/0269881116679368"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Krebs\u00a0TS, Johansen\u00a0P\u00d8. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26: 994\u20131002. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22406913&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881112439253","DOI":"10.1177\/0269881112439253"},{"key":"ref=4","unstructured":"Nichols\u00a0DE. Psychedelics. Pharmacol Rev 2016; 68: 264\u2013355. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26841800&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1124%2Fpr.115.011478"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Nutt\u00a0DJ, King\u00a0LA, Phillips\u00a0LD. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376: 1558\u201365. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21036393&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS0140-6736(10)61462-6","DOI":"10.1016\/S0140-6736(10)61462-6"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Carhart-Harris\u00a0RL, Goodwin\u00a0GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017; 42: 2105\u201313. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28443617&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fnpp.2017.84","DOI":"10.1038\/npp.2017.84"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Studerus\u00a0E, Kometer\u00a0M, Hasler\u00a0F et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 2011; 25: 1434\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20855349&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881110382466","DOI":"10.1177\/0269881110382466"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Bogenschutz\u00a0MP, Forcehimes\u00a0AA, Pommy\u00a0JA et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015; 29: 289\u201399. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25586396&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881114565144","DOI":"10.1177\/0269881114565144"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Carhart-Harris\u00a0RL, Bolstridge\u00a0M, Rucker\u00a0J et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3: 619\u201327. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27210031&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS2215-0366(16)30065-7","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Griffiths\u00a0RR, Johnson\u00a0MW, Carducci\u00a0MA et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30: 1181\u201397. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27909165&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881116675513","DOI":"10.1177\/0269881116675513"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Grob\u00a0CS, Danforth\u00a0AL, Chopra\u00a0GS et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68: 71\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20819978&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Farchgenpsychiatry.2010.116","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Johnson\u00a0MW, Garcia-Romeu\u00a0A, Cosimano\u00a0MP et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014; 28: 983\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25213996&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881114548296","DOI":"10.1177\/0269881114548296"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Moreno\u00a0FA, Wiegand\u00a0CB, Taitano\u00a0EK et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17196053&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4088%2FJCP.v67n1110","DOI":"10.4088\/JCP.v67n1110"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Ross\u00a0S, Bossis\u00a0A, Guss\u00a0J et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30: 1165\u201380. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27909164&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881116675512","DOI":"10.1177\/0269881116675512"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Os\u00f3rio\u00a0FL, Sanches\u00a0RF, Macedo\u00a0LR et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 2015; 37: 13\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25806551&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1590%2F1516-4446-2014-1496","DOI":"10.1590\/1516-4446-2014-1496"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Gasser\u00a0P, Holstein\u00a0D, Michel\u00a0Y et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014; 202: 513\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24594678&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FNMD.0000000000000113","DOI":"10.1097\/NMD.0000000000000113"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Orsolini\u00a0L, Papanti\u00a0GD, De Berardis\u00a0D et al. The \"endless trip\" among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. a systematic review. Front Psychiatry 2017; 8: 240. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29209235&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffpsyt.2017.00240","DOI":"10.3389\/fpsyt.2017.00240"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Krebs\u00a0TS, Johansen\u00a0P\u00d8. Psychedelics and mental health: a population study. PLoS One 2013; 8: e63972. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23976938&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pone.0063972","DOI":"10.1371\/journal.pone.0063972"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Hendricks\u00a0PS, Thorne\u00a0CB, Clark\u00a0CB et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol 2015; 29: 280\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25586402&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881114565653","DOI":"10.1177\/0269881114565653"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Cohen\u00a0S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 130: 30\u201340. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13811003&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2F00005053-196001000-00005","DOI":"10.1097\/00005053-196001000-00005"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Johnson\u00a0M, Richards\u00a0W, Griffiths\u00a0R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008; 22: 603\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18593734&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F0269881108093587","DOI":"10.1177\/0269881108093587"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Quintana\u00a0DS, Steen\u00a0NE, Andreassen\u00a0OA. The promise of intranasal esketamine as a novel and effective antidepressant. JAMA Psychiatry 2018; 75: 123\u20134. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29282452&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamapsychiatry.2017.3738","DOI":"10.1001\/jamapsychiatry.2017.3738"},{"key":"ref=23","unstructured":"ClinicalTrials.gov. U.S. National Library of Medicine. https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=&term=psychedelic&cntry=&state=&city=&dist (30.8.2018)."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Psykedeliske stoffer i behandling av angst, depresjon og avhengighet"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:19:48Z","timestamp":1781702388000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2018\/11\/oversiktsartikkel\/psykedeliske-stoffer-i-behandling-av-angst-depresjon-og-avhengighet"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":23,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.17.1110","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]}}}